SciSparc has been granted an approval from the Federal Institute for Drugs and Medical Devices in Germany for its Phase IIb clinical trial to use SCI-110 for treating adults with Tourette Syndrome at the Hannover Medical School in Hannover, Germany. The Phase IIb clinical trial will be conducted at three global leading centers of excellence: the Yale Child Study Center at the Yale School of Medicine in Connecticut, USA, the Hannover Medical School in Hannover, Germany, and at the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. The Company has already secured the Institutional Review Board approvals from all three clinical sites as well as the Israeli Ministry of Health’s approval for the clinical trial at Sourasky. Authorization from the BfArM has been granted on the condition that some additional information for the release and stability of SCI-110 will be provided within 90 days.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SPRC:
- SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
- SciSparc announces IRB approval to conduct Phase IIb trial in TS
- SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
- SciSparc, Clearmind to conduct study of obesity, metabolic syndrome treatment
- SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals